- Trials with a EudraCT protocol (408)
 - Paediatric studies in scope of Art45 of the Paediatric Regulation (16)
 
		
	   		
	   		    
                    
                   	
                   	    408 result(s) found for: Schizophrenia.
                    
                
			
   			
		
		Displaying page 1 of 21.
	
	
	| EudraCT Number: 2010-024488-42 | Sponsor Protocol Number: 2010-024488-42-PACS | Start Date*: 2011-01-31 | |||||||||||||||||||||||||||||||
| Sponsor Name:Aalborg University Hospital, Aalborg Psychiatric Hospital, Centre for Psychosisresearch | |||||||||||||||||||||||||||||||||
| Full Title: Pregabalin for anxiety comorbidity in patients with schizophrenia (PACS) - A Double-blinded Randomized Placebo Controlled Trial | |||||||||||||||||||||||||||||||||
| Medical condition: anxiety-comorbidity to schizophrenia | |||||||||||||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-009215-22 | Sponsor Protocol Number: BISCLOZ | Start Date*: 2009-03-26 | |||||||||||||||||||||||||||||||
| Sponsor Name:Aalborg Psychiatric Hospital, Centre for Skizophrenia | |||||||||||||||||||||||||||||||||
| Full Title: “Treating clozapine-induced sinustachycardia (BISCLOZ).” | |||||||||||||||||||||||||||||||||
| Medical condition: Clozapine induced sinuatachycardia treated with bisoprolol. | |||||||||||||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-000800-34 | Sponsor Protocol Number: H8Y-MC-HBBI | Start Date*: 2007-08-14 | |||||||||||||||||||||||||||||||
| Sponsor Name:Eli Lilly and Company Ltd. | |||||||||||||||||||||||||||||||||
| Full Title: A Multi-center, Inpatient, Phase 2, Double-blind, Placebo-controlled Dose Ranging Study of LY2140023 in Patients with DSM-IV Schizophrenia. | |||||||||||||||||||||||||||||||||
| Medical condition: Patients must have a diagnosis of Schizophrenia as defined in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (Disorganized, 295.10; Catatonic, 295.20; Paranoid, 295.... | |||||||||||||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) PT (Completed) AT (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-008366-13 | Sponsor Protocol Number: 3.0edition | Start Date*: 2009-03-17 | |||||||||||||||||||||||||||||||
| Sponsor Name:Unit for Psychiatric Research | |||||||||||||||||||||||||||||||||
| Full Title: Comparison of the effects of Sertindole and Olanzapine on Cognition | |||||||||||||||||||||||||||||||||
| Medical condition: Cognitive deficits in patients with schizophrenia | |||||||||||||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) SE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-000479-11 | Sponsor Protocol Number: 12396A | Start Date*: 2008-07-21 | ||||||||||||||||||||||||||
| Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||||||||||||
| Full Title: A randomised, double-blind, parallel-group, active-controlled, flexible dose study exploring the efficacy and safety of 12 weeks treatment with Lu 31-130 in patients with schizophrenia | ||||||||||||||||||||||||||||
| Medical condition: Lu 31-130 is under development by H. Lundbeck A/S as an antipsychotic in the treatment of schizophrenia | ||||||||||||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: CZ (Completed) FR (Completed) ES (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2010-022181-28 | Sponsor Protocol Number: 13639A | Start Date*: 2011-02-07 | ||||||||||||||||||||||||||
| Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||||||||||||
| Full Title: A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia | ||||||||||||||||||||||||||||
| Medical condition: Schizophrenia | ||||||||||||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: FI (Completed) EE (Completed) CZ (Completed) PL (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2019-000470-36 | Sponsor Protocol Number: SEP361-301 | Start Date*: Information not available in EudraCT | ||||||||||||||||
| Sponsor Name:Sunovion Pharmaceuticals Inc. | ||||||||||||||||||
| Full Title: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia | ||||||||||||||||||
| Medical condition: Schizophrenia | ||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BG (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2019-000696-16 | Sponsor Protocol Number: SEP361-303 | Start Date*: 2019-09-06 | ||||||||||||||||
| Sponsor Name:Sunovion Pharmaceuticals Inc. | ||||||||||||||||||
| Full Title: An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia | ||||||||||||||||||
| Medical condition: Schizophrenia | ||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: LV (Completed) BG (Completed) HR (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2006-004708-38 | Sponsor Protocol Number: 1326 | Start Date*: 2006-08-25 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA | |||||||||||||
| Full Title: Randomized evaluation of the effectiveness of clozapine and aripiprazole versus clozapine and haloperidol in the treatment of schizofrenia. An independent, pragmatic, multicentre, parallel-group, s... | |||||||||||||
| Medical condition: Schizophrenia | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-024119-15 | Sponsor Protocol Number: rs4680-tolcapona | Start Date*: 2014-04-10 | |||||||||||
| Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | |||||||||||||
| Full Title: EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680 | |||||||||||||
| Medical condition: Esquizofrenia crónica controlada. (10 pacientes con el genotipo val/val y 10 pacientes con el genotipo met/met) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Restarted) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-003834-34 | Sponsor Protocol Number: NBI-1065844-CIAS2023 | Start Date*: 2023-02-23 | |||||||||||
| Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizop... | |||||||||||||
| Medical condition: Cognitive Impairment Associated With Schizophrenia | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001315-71 | Sponsor Protocol Number: DPSANARI2012 | Start Date*: 2013-10-17 | |||||||||||
| Sponsor Name:Mercedes Zumarraga Ortiz | |||||||||||||
| Full Title: Dopaminergic genotype of schizophrenic patients and the benefit of adjunctive aripiprazole to risperidone treatment. The effect on hormonal and metabolic measures | |||||||||||||
| Medical condition: schizophrenia | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-002193-45 | Sponsor Protocol Number: ALK3831-302 | Start Date*: 2013-12-27 | |||||||||||
| Sponsor Name:Alkermes Inc. | |||||||||||||
| Full Title: A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALK 3831, in Adults with Schizophrenia Treated with Olanzapine | |||||||||||||
| Medical condition: Schizophrenia | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005513-40 | Sponsor Protocol Number: 2012-005513-40 | Start Date*: 2013-05-28 | |||||||||||
| Sponsor Name:HYKS Psykiatrikeskus | |||||||||||||
| Full Title: Histamine H2 antagonism as adjuvant therapy in treatment resistant schizophrenia | |||||||||||||
| Medical condition: Schizophrenia | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-002682-40 | Sponsor Protocol Number: 2005/150 | Start Date*: 2006-08-07 | |||||||||||
| Sponsor Name:Aalborg Psychiatric Hospital, Research Unit | |||||||||||||
| Full Title: Augmenting clozapine with sertindole - A double-blinded randomized placebo study (SERCLOZ) | |||||||||||||
| Medical condition: Treatment resistant schizophrenia | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-003996-20 | Sponsor Protocol Number: ALK9072-003EXT | Start Date*: 2013-03-28 | |||||||||||||||||||||
| Sponsor Name:Alkermes, Inc. | |||||||||||||||||||||||
| Full Title: A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects with Stable Schizophrenia | |||||||||||||||||||||||
| Medical condition: stable schizophrenia | |||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BG (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2007-000577-38 | Sponsor Protocol Number: PSZ-3002 | Start Date*: 2007-08-16 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
| Full Title: A 2-Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia | |||||||||||||
| Medical condition: Adolescents Schizphrenia | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) BE (Completed) EE (Completed) PL (Completed) BG (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003373-15 | Sponsor Protocol Number: ALK3831-A305 | Start Date*: 2016-04-25 | |||||||||||
| Sponsor Name:Alkermes Inc | |||||||||||||
| Full Title: A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects with Acute Exacerbation of Schizophrenia | |||||||||||||
| Medical condition: Schizophrenia | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) HU (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-020370-42 | Sponsor Protocol Number: NN25310 | Start Date*: 2011-01-06 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n... | |||||||||||||
| Medical condition: Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics. | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-001441-26 | Sponsor Protocol Number: 12450A | Start Date*: 2009-04-01 | ||||||||||||||||
| Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||
| Full Title: A randomised, double-blind, parallel-group, fixed dose study exploring the efficacy and safety of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia. | ||||||||||||||||||
| Medical condition: Lu AE58054 is under development by H.Lundbeck A/S as an anti-psychotic in the treatment of schizophrenia | ||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) DE (Completed) BE (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
    	Query did not match any studies.